Kezar Life Sciences, Inc. (KZR) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16
	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	71.2	54.7	43.0	37.3	6.6	2.3	1.6
General and administrative					6.6	2.3	1.6
Research and development					18.1	6.5	7.4
Other operating expenses	-71.2	-54.7	-43.0	-37.3
EBITDA [+]	1.0	1.5	1.5	1.3	-24.0	-8.6	-8.8
EBITDA growth	-32.3%	-2.2%	18.7%	-105.4%	180.3%	-3.0%
Depreciation and amortization	1.0	1.5	1.5	1.3	0.7	0.2	0.2
EBIT [+]	0.0	0.0	0.0	0.0	-24.7	-8.7	-9.0
EBIT growth				-100.0%	182.6%	-2.7%
Interest income, net [+]					1.6	0.2
Interest expense	1.2	0.2
Interest income					1.6	0.2
Other income (expense), net	-67.1	-54.5	-41.7	-35.1
Pre-tax income	-68.2	-54.6	-41.7	-35.1	-23.2	-8.5	-9.0
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-68.2	-54.6	-41.7	-35.1	-23.2	-8.5	-9.0

Basic EPS [+]	($1.01)	($1.04)	($0.95)	($1.84)	($2.26)	($14.21)	($26.56)
Growth	-2.2%	9.2%	-48.4%	-18.5%	-84.1%	-46.5%
Diluted EPS [+]	($1.01)	($1.04)	($0.95)	($1.84)	($2.26)	($14.21)	($26.56)
Growth	-2.2%	9.2%	-48.4%	-18.5%	-84.1%	-46.5%

Shares outstanding (basic) [+]	67.4	52.8	44.0	19.1	10.3	0.6	0.3
Growth	27.7%	19.9%	130.6%	85.9%	1612.8%	77.1%
Shares outstanding (diluted) [+]	67.4	52.8	44.0	19.1	10.3	0.6	0.3
Growth	27.7%	19.9%	130.6%	85.9%	1612.8%	77.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.